Yes, product liability and dangerous drug lawsuits are surging in 2026, and the numbers tell a striking story. Over 197,000 cases are currently pending in product liability multidistrict litigations (MDLs) as of February 2026, with settlements and jury awards reaching unprecedented levels. The top 10 product liability class actions alone reached $17.9 billion in 2025, part of a broader $80 billion landscape of all class action settlements.
This surge reflects a fundamental shift: consumers are holding manufacturers accountable for products that harm them, and the courts are increasingly siding with plaintiffs. The most visible examples are the talcum powder litigation against Johnson & Johnson, with 69,600 cases still pending, and the emerging wave of GLP-1 drug litigation—with over 4,400 plaintiffs alleging the diabetes and weight-loss medications cause gastroparesis (stomach paralysis), and a separate vision loss MDL established in December 2025. These aren’t isolated incidents; they’re part of a systemic trend where pharmaceutical companies and product manufacturers face growing legal exposure for inadequate warnings, hidden risks, and prioritized profits over safety. This article examines what’s driving the surge, who’s affected, what settlements are paying out, and what your rights are if a dangerous product has harmed you.
Table of Contents
- Why Has Product Liability Litigation Grown So Dramatically Since 2013?
- What Are Plaintiffs Actually Winning—And How Much Are Settlements Worth?
- The Major Active Litigation Cases Reshaping Product Liability in 2026
- How Do You Know If You Have a Product Liability Claim, and What Needs to Be Proven?
- The Hidden Scale of Drug-Related Injuries and Pharmaceutical Safety Issues
- The FTC-Express Scripts Settlement and What It Means for Drug Pricing Accountability
- What’s Ahead for Product Liability and Dangerous Drug Litigation in 2026 and Beyond?
- Conclusion
Why Has Product Liability Litigation Grown So Dramatically Since 2013?
The explosion in product liability lawsuits isn’t random—it reflects both a documented trend and a shift in how courts treat manufacturer liability. Product liability cases nearly doubled from 3,342 in 2013 to 5,826 in 2022, and that trajectory has continued accelerating into 2026. Several factors drive this growth. First, the internet and social media have made it easier for injured people to find each other and learn about litigation options.
What was once an isolated injury is now instantly searchable; a victim of talcum powder ovarian cancer can now discover that thousands of others faced the same diagnosis. Second, and more legally significant, courts have consistently ruled that FDA approval does not shield manufacturers from liability if the warnings were inadequate or misleading. This is a critical distinction: the FDA approves a drug for market, but that approval does not mean the company told doctors and patients about all the risks. When new evidence emerges—especially evidence the company knew about or should have known about—lawsuits follow. GLP-1 drugs (like Ozempic and Wegovy) are a perfect example: they were FDA-approved for diabetes and weight loss, but as reports of vision loss and stomach paralysis emerged in real-world use, manufacturers faced immediate litigation rather than immunity.
What Are Plaintiffs Actually Winning—And How Much Are Settlements Worth?
If you’re considering whether a case is worth pursuing, the financial data matters. Sixty-seven percent of product liability cases end in plaintiff settlements rather than dismissals or defense verdicts, which is a strong win rate. The payouts reflect the seriousness of the injuries: median jury awards are nearing $4 million, while average settlements from jury verdicts are exceeding $7 million. However, not all cases reach that level.
class action settlements vary dramatically depending on the type of injury, the strength of evidence, and the number of claimants. For individual claimants, the settlement amount depends on factors like the severity of your injury, documented medical expenses, lost wages, and how much product you purchased or used. A talcum powder settlement, for instance, typically pays more for ovarian cancer diagnoses than for benign conditions. Conversely, in mass-market settlements with hundreds of thousands of claimants, individual payouts tend to be smaller because the settlement pool is divided. Someone claiming $50,000 in medical bills for a serious injury will receive a higher percentage recovery than someone with a $500 claim for a defective product—but they may both ultimately settle for less than they’d win at trial.
The Major Active Litigation Cases Reshaping Product Liability in 2026
Three major litigation fronts dominate the current landscape and will likely define product liability law throughout 2026. The talcum powder litigation against Johnson & Johnson remains the largest by volume, with 69,600 cases still pending as of February 2026, even after billions in settlements. These cases allege that talc products cause ovarian cancer and mesothelioma, with evidence suggesting J&J knew about asbestos contamination but failed to adequately warn consumers. The litigation has already paid billions to victims, but the sheer number of pending cases shows no signs of abating.
The GLP-1 litigation represents the newest frontier. Over 4,400 plaintiffs are currently suing over gastroparesis (stomach paralysis) allegedly caused by drugs like Ozempic and Wegovy, with a separate vision loss MDL established in December 2025. These lawsuits target one of the most widely prescribed medication classes, meaning the total universe of potential plaintiffs is massive. Additionally, 1,700+ Depo-Provera lawsuits remain pending in federal court, alleging that the injectable contraceptive caused bone density loss and other serious side effects. Together, these three litigation fronts represent roughly 75,000+ pending cases and billions in potential exposure for manufacturers.
How Do You Know If You Have a Product Liability Claim, and What Needs to Be Proven?
To have a viable product liability claim, three elements typically must be present: the product was defective either in design or manufacture, or the manufacturer failed to provide adequate warnings about known risks; you were injured by using the product as intended; and your injuries caused documented damages—medical bills, lost wages, pain and suffering. The burden falls on the plaintiff to prove these elements, but the good news is that discovery (the legal process where both sides exchange evidence) often reveals internal company documents showing the manufacturer knew about risks. However, just because a product caused your injury doesn’t automatically mean you have a case.
If you misused the product in a way a reasonable person would not, or if you ignored clear warnings, liability becomes much harder to prove. For example, if a medication carries a black-box warning (the FDA’s most serious warning) about a specific risk, and that risk materialized, your claim is stronger. Conversely, if the risk was completely unknown at the time you used the product, liability may fall on the manufacturer for failing to discover and warn about it. The critical question is whether the company knew or should have known about the danger and failed to disclose it.
The Hidden Scale of Drug-Related Injuries and Pharmaceutical Safety Issues
While major lawsuits grab headlines, the underlying public health problem is staggering. The U.S. experiences approximately 1.5 million emergency department visits annually caused by adverse drug reactions. That’s not pharmaceutical companies’ estimates or worst-case scenarios—that’s documented ER visits. Additionally, in just the first half of 2024, 384.2 million pharmaceutical units were recalled, indicating systemic quality control and safety issues across the industry.
These numbers explain why litigation is surging: when that many people are injured, some will eventually sue. The warning here is important: not every adverse drug reaction is grounds for a lawsuit. If you took a medication exactly as prescribed, experienced side effects listed in the package insert, and had no way of knowing about unlisted dangers, you still may not have a claim—unless evidence later emerges that the manufacturer hid the risk. However, if a medication caused an injury that was not properly disclosed, or if manufacturing defects led to contamination or improper dosing, liability is much clearer. The 1.5 million annual ER visits suggest there’s substantial injury happening, but only a fraction becomes litigation.
The FTC-Express Scripts Settlement and What It Means for Drug Pricing Accountability
In February 2026, the FTC secured a landmark settlement with Express Scripts that will save patients an estimated $7 billion on insulin costs over the next 10 years. This settlement, while not technically a class action product liability case, illustrates how regulators are increasingly holding pharmaceutical intermediaries accountable for pricing schemes that harm consumers. Express Scripts, a pharmacy benefit manager, was accused of using anticompetitive practices that artificially inflated insulin costs for diabetic patients.
This case is relevant to product liability discussions because it demonstrates that companies can face massive financial consequences not just for defective products, but for practices that restrict access to medicines or inflate prices while concealing the true reasons for cost increases. For patients harmed by high medication costs—including insulin rationing that led to deaths—this settlement signals that regulators and courts are taking these issues seriously. While the settlement focuses on pricing rather than product defects, it shows the same legal principle at work: when companies prioritize profits over patient welfare and conceal the impact, they face accountability.
What’s Ahead for Product Liability and Dangerous Drug Litigation in 2026 and Beyond?
The trajectory is clear: product liability litigation will continue expanding in 2026. Several emerging areas suggest future litigation waves. The GLP-1 litigation, still in its early stages, will likely grow as more users report vision loss, gastroparesis, and other complications. Medical device litigation—including orthopedic implants, insulin pumps, and pacemakers—continues to generate new cases as long-term complications emerge.
Additionally, newer drug classes and devices will face scrutiny similar to what GLP-1 drugs face now, particularly if early warnings about safety issues are ignored or downplayed. The regulatory environment is also shifting. The FTC’s willingness to pursue pricing settlements, combined with FDA enforcement actions and state attorneys general pursuing product liability cases, means manufacturers face pressure from multiple directions simultaneously. Class actions that once took 10 years to resolve are settling faster as companies recognize the financial and reputational costs of prolonged litigation. For consumers, this acceleration means shorter wait times for settlement payouts—but it also means the compensation pool is determined more quickly, sometimes before all potential claimants are identified.
Conclusion
Product liability and dangerous drug lawsuits are surging in 2026 because three decades of FDA approvals did not prevent manufacturers from hiding risks, cutting corners on quality, or prioritizing profits over safety. The 197,000+ pending cases, $17.9 billion in top-tier settlements, and 67% plaintiff success rate are not anomalies—they reflect a systematic problem where consumer injuries accumulate faster than manufacturers disclose the dangers. The talcum powder litigation, GLP-1 cases, and Depo-Provera lawsuits all tell the same story: companies knew or should have known about risks and failed to warn adequately.
If you believe a product has harmed you, the financial and legal landscape has shifted in your favor. Settlements now exceed $7 million on average for serious injuries, and the liability standard is clear: FDA approval does not shield manufacturers, and internal company documents often reveal knowledge of risks. The next step is to document your injury, gather medical records, and consult with a qualified attorney who handles product liability cases. With over 197,000 cases currently pending, you’re far from alone—and the courts have consistently sided with injured consumers.